Anti-metastatic activity of MDP-L-alanyl-cholesterol incorporated into various types of nanocapsules.

Abstract

A lipophilic immunomodulator (MTP-Chol) was included in nanocapsules prepared from different polymers and the anti-metastatic effects of the resulting drug delivery systems were evaluated in a murine model of liver metastases. Loaded nanocapsules were effective if they were given 2 days before tumor inoculation. Neither the nature of the polymer nor the total dose of immunomodulator affected the antimetastatic capacity. However, enhanced anti-metastatic activity was obtained when indomethacin nanocapsules were associated with MTP-Chol nanocapsules. These results show that nanocapsules containing an immunomodulator possess anti-metastatic activity, but only when given as a prophylactic treatment; this would correspond, in the clinic, to patients undergoing surgery for a primary tumor and at risk of developing liver metastases.

• Authors: G Barratt, F Puisieux, W P Yu, C Foucher, H Fessi, J P Devissaguet
• Journal: International journal of immunopharmacology (Int J Immunopharmacol) 1994 May-Jun Vol. 16 Issue 5-6 Pg. 457-61 ISSN: 0192-0561 [Print] England
• PMID: 7927993 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Capsules
• Polymers
• Acetylmuramyl-Alanyl-Isoglutamine
• muramylNAc-Ala-isoGln-Lys-tripeptide
• Cholesterol

Topics

• Acetylmuramyl-Alanyl-Isoglutamine (administration & dosage, analogs & derivatives)
• Animals
• Antineoplastic Agents (administration & dosage)
• Capsules
• Cholesterol (administration & dosage)
• Liver Neoplasms, Experimental (prevention & control, secondary)
• Mice
• Polymers (administration & dosage)